The study examined the connection between mental health diagnoses and GLP-1 medications, which have been used for glucose control in diabetic patients, with some recently receiving FDA approval for weight management in obese patients. GLP-1 medications include popular name brands such as Ozempic, Wegovy, Zepbound and Mounjaro.
The study analyzed more than 3 million diabetic patients and almost 1 million non-diabetic patients taking these medications and their various active ingredients.
It found that diabetic patients taking medications with Semaglitude as the active ingredient, like Ozempic for type 2 diabetes and Wegovy for weight loss, were 45% and 44% less likely to be diagnosed with depression and anxiety, respectively.
Meanwhile, diabetic patients taking medications with tirzepatide as the active ingredient were 65% less likely to be diagnosed with depression and 60% less likely to be diagnosed with anxiety.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
